Key result
Higher indoxyl sulfate linked to ~10-fold higher six-month event risk after primary PCI.
Why the study?
The prognostic value of serum indoxyl sulfate level after acute coronary syndrome was not established.
Does serum indoxyl sulfate level predict six-month composite events in patients with acute coronary syndrome after primary PCI?
Cohort (n=98)
No
Does serum indoxyl sulfate level predict six-month composite events in patients with acute coronary syndrome after primary PCI?
Answers are grounded in this paper and cite their sources.
Serum indoxyl sulfate level serves as an independent prognostic biomarker for adverse events in ACS patients post-PCI, providing incremental value over traditional risk factors.
AIM: We investigated whether indoxyl sulfate (IS), a protein-bound uremic toxin, predicts prognosis after acute coronary syndrome (ACS). METHODS: Serum IS level was determined prospectively in 98 patients who underwent successful primary percutaneous coronary intervention for ACS. Patients on hemodialysis were excluded. The endpoint of this study was six-month composite events including death, nonfatal myocardial infarction, heart failure requiring hospitalization, and adverse bleeding events. RESULTS: During the mean follow-up period of 168 days, composite events occurred in 13.3% of cases. Serum IS level was significantly higher in subjects who developed composite events than in those without events (0.14±0.11 mg/dl vs. 0.06±0.04 mg/dl; p<0.001). After adjusting for confounding factors, a Cox proportional hazard analysis revealed that the IS level (hazard ratio (HR): 10.6; 95% confidence interval (CI): 1.63-69.3, p=0.01), hemoglobin level (HR: 0.61; 95% CI: 0.43-0.87; p<0.01), and left ventricular ejection fraction (LVEF) (HR: 0.95; 95% CI: 0.91-0.99; p=0.03) were independent predictive factors of composite events. Furthermore, IS level significantly conferred additional value to the combined established risks of LVEF and hemoglobin level for predicting the incidence of composite events (area under the curve: 0.82 vs. 0.88, p=0.01; net reclassification improvement: 0.67, p=0.01; and integrated discrimination improvement: 0.15, p<0.01). CONCLUSIONS: The assessment of serum IS level has prognostic utility for the management of ACS.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2018) conducted a cohort in Acute Coronary Syndrome (n=98). Serum indoxyl sulfate (IS) level vs. Lower serum indoxyl sulfate level was evaluated on Six-month composite events (death, nonfatal myocardial infarction, heart failure requiring hospitalization, and adverse bleeding events) (HR 10.6, 95% CI 1.63-69.3, p=0.01). Higher serum indoxyl sulfate levels independently predicted a higher incidence of six-month composite events in patients with acute coronary syndrome after successful primary PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: